Real-world experience of dacomitinib in EGFR mutated advanced NSCLC: A single center experience from India.

Bivas Biswas,Sandip Ganguly,Joydeep Ghosh,Somnath Roy,Rupsa Bakshi,Deepak Dabkara

Real-world experience of dacomitinib in EGFR mutated advanced NSCLC: A single center experience from India.

2021

Bivas Biswas
Sandip Ganguly
Joydeep Ghosh
Somnath Roy
Rupsa Bakshi
Deepak Dabkara

e21043Background: Dacomitinib is an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) approved in advanced non-small cell lung cancer (NSCLC) with mutated EGFR. Lite...

Keywords:

Cancer research
non small cell
Dacomitinib
Medicine
Single Center
Tyrosine-kinase inhibitor
Epidermal growth factor receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations